

REMARKS/ARGUMENTS

Status of the Claims

Upon entry of the present amendment, claims 26, 35-37 and 52-62 are pending. Claim 58 is amended. Claims 63-69 are canceled without disclaimer or prejudice to renewal.

Claim 58 is amended to set forth a B220 CD45 isoform. Support is found, for example, on page 7, lines 26-28.

No new matter is added by the present amendments, and the Examiner is respectfully requested to enter them.

Advisory Action

In response to the Advisory Action, Applicants have canceled claims 63-69 and amended claim 58.

With respect to claims 63-69, Applicants reserve the right to pursue these claims in a continuation or divisional application.

With respect to the Examiner's maintained rejection of claim 58 under 35 U.S.C. § 102(a), Applicants have amended claim 58, but respectfully disagree with the Examiner's position. U.S. Provisional Application No. 60/113,680 discloses detecting all CD45 isoforms using antibody 30-F11 on page 6, lines 23-24.

Appl. No. 09/857,233
Amdt. dated April 30, 2007
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1644


PATENT

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance and an action to that end is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jennifer L. Wahlsten
Reg. No. 46,226

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
Attachments
JLW:jlw
61041071 v1